Soma — Competitive Intelligence Brief

Soma (CARISOPRODOL) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Muscle Relaxant [EPC]. Area: Neuroscience.

marketed Muscle Relaxant [EPC] Neuroscience Small molecule

Target snapshot

Soma (CARISOPRODOL) — Mylan Speciality Lp. Carisoprodol's mechanism for relieving acute musculoskeletal pain is unclear, but it involves altered interneuronal activity in the spinal cord and brain.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Soma TARGET	CARISOPRODOL	Mylan Speciality Lp	marketed	Muscle Relaxant [EPC]		1959-01-01
Atracurium	Atracurium Besylate	Pfizer	marketed	Nondepolarizing skeletal muscle relaxant	Cholinergic receptor sites on motor end-plate	1983-01-01
Amrix	CYCLOBENZAPRINE		marketed	Muscle Relaxant	Histamine H1 receptor	1977-01-01
Ryanodex	DANTROLENE	Ph Health	marketed	Skeletal Muscle Relaxant	Ryanodine receptor 1	1974-01-01
Skelaxin	METAXALONE	Pfizer	marketed	Muscle Relaxant [EPC]		1962-01-01
Parafon Forte Dsc	CHLORZOXAZONE	Johnson & Johnson	marketed	Muscle Relaxant [EPC]	Nitric oxide synthase, endothelial	1958-01-01
Robaxin	METHOCARBAMOL	Hikma	marketed	Muscle Relaxant [EPC]	Carbonic anhydrase 1	1957-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

• 2044-10-09 — Robaxin · 12390439 · Formulation · US

Sponsor landscape (Muscle Relaxant [EPC] class)

1. Hikma · 1 drug in this class
2. Johnson & Johnson · 1 drug in this class
3. Mylan Speciality Lp · 1 drug in this class
4. Pfizer · 1 drug in this class